Volume 14, Issue 2 (2-2026)                   JoMMID 2026, 14(2): 115-123 | Back to browse issues page

Ethics code: IR.SBMU.REC.1394.100

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Donyavi T, Chegeni R, Bandehpour M, Mohammadi-Yeganeh S, Zahedi- Zavaram H, Kazemi B et al . Evaluation of Transgenic Iranian Lizard Leishmania Encoding Human IL-12 as a Candidate Vaccine Against Experimental Cutaneous Leishmaniasis in Susceptible BALB/c Mice. JoMMID 2026; 14 (2) :115-123
URL: http://jommid.pasteur.ac.ir/article-1-697-en.html
Evaluation of Transgenic Iranian Lizard Leishmania Encoding Human IL-12 as a Candidate Vaccine Against Experimental Cutaneous Leishmaniasis in Susceptible BALB/c Mice
Tahereh Donyavi , Rouzbeh Chegeni , Mojgan Bandehpour , Samira Mohammadi-Yeganeh , Hadi Zahedi- Zavaram , Bahram Kazemi * , Mehdi Namjoomanesh
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran & Cellular and Molecular Biology Research Center, Systems Biology Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (921 Views)
Introduction: Leishmaniasis is a neglected tropical disease that causes significant morbidity worldwide, particularly in developing countries. Despite ongoing efforts, there is no widely approved human vaccine against this disease. Live, non-pathogenic organisms such as Leishmania tarentolae have emerged as promising candidates for vaccine development due to their safety profile and ability to present antigens in a native context. This study aimed to evaluate transgenic Iranian Lizard Leishmania (I.L.L.) encoding human IL-12 (hIL-12) as a candidate vaccine against experimental cutaneous leishmaniasis in susceptible BALB/c mice. Methods: BALB/c mice were divided into six groups and immunized subcutaneously with either transgenic L. tarentolae-hIL-12 (G1 and G2), wild-type L. tarentolae (G3 and G4), or RPMI-1640 medium (G5 and G6). Three weeks post-immunization, animals received a booster injection. Two weeks after the booster, challenged groups (G1, G3, and G5) were infected with Leishmania major promastigotes. Lesion progression was measured weekly for 11 weeks. IgG2a responses were assessed using ELISA, while cytokine responses (IFN-γ, IL-17, IL-10, TNF-α) were quantified after stimulation with soluble L. major antigen (SLA). Parasite burden in spleens was evaluated by real-time PCR. Results: Mice vaccinated with transgenic I.L.L.-hIL-12 developed significantly stronger cellular and humoral immune responses than the control groups. Elevated IFN-γ, IL-17 and IgG2a levels indicated a predominantly Th1-biased immune response, while increased IL-10 production suggested a concomitant regulatory response. Vaccinated mice also exhibited smaller lesion sizes and lower splenic parasite burdens than the control groups, indicating partial protection against L. major infection. Conclusion: The transgenic L. tarentolae-hIL-12 strain effectively induced protective immunity in susceptible BALB/c mice, supporting its potential as a novel and safe live vaccine platform for cutaneous leishmaniasis due to L. major.
Keywords: Leishmania tarentolae, Leishmania major, Interleukin-12, Vaccines, Parasite burden
Full-Text [PDF 1078 kb]   (87 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2024/12/2 | Accepted: 2026/02/21 | Published: 2026/09/7
References
1. Scott P, Novais FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. 2016; 16 (9): 581-92. [DOI:10.1038/nri.2016.72] [PMID]
2. World Health Organization. Visceral leishmaniasis and HIV coinfection [Internet]. Geneva: World Health Organization; 2022 Jun [cited 2025 Apr 29]. Available from: https://www.who.int/news/item/08-06-2022-visceral-leishmaniasis-and-HIV-coinfection
3. Sundar S, Singh J, Singh VK, Agrawal N, Kumar R. Current and emerging therapies for the treatment of leishmaniasis. Expert Opin Orphan Drugs. 2024; 12 (1): 19-32. [DOI:10.1080/21678707.2024.2335248]
4. Gillespie PM, Beaumier CM, Hay M, Ward JM, Reed SG. Status of vaccine research and development of vaccines for leishmaniasis. Vaccine. 2016; 34 (26): 2992-5. [DOI:10.1016/j.vaccine.2015.12.071] [PMID] [PMCID]
5. Dantas-Torres F, Ferreira DRA, de Lima-Junior J, de Paiva-Cavalcanti M. Leishmania vaccines: the current situation with its promising aspect for the future. Pathogens. 2019; 8 (4): 263.
6. Ayala A, Llanes A, Lleonart R, Restrepo CM. Advances in Leishmania vaccines: current development and future prospects. Pathogens. 2024; 13 (9): 812. [DOI:10.3390/pathogens13090812] [PMID] [PMCID]
7. Dinc R. Leishmania vaccines: the current situation with its promising aspect for the future. Korean J Parasitol. 2022; 60 (6): 379-91. [DOI:10.3347/kjp.2022.60.6.379] [PMID] [PMCID]
8. Volpedo G, Bhattacharya P, Gannavaram S, Pacheco-Fernandez T, Oljuskin T, Dey R, et al. The history of live attenuated centrin gene-deleted Leishmania vaccine candidates. Pathogens. 2022; 11 (4): 431. [DOI:10.3390/pathogens11040431] [PMID] [PMCID]
9. Haghdoust S, Noroozbeygi M, Hajimollahoseini M, Masooleh MM, Yeganeh F. A candidate vaccine composed of live nonpathogenic Iranian Lizard Leishmania mixed with chitin microparticles protects mice against Leishmania major infection. Acta Trop. 2022; 227: 106298. [DOI:10.1016/j.actatropica.2021.106298] [PMID]
10. Raymond F, Boisvert S, Roy G, Ritt JF, Ouellette M, Corbeil J, et al. Genome sequencing of Leishmania tarentolae reveals the limits of a non-pathogenic trypanosomatid model. PLoS Negl Trop Dis. 2012; 6 (3): e1516.
11. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+ CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002; 420 (6915): 502-7. [DOI:10.1038/nature01152] [PMID]
12. Zanganeh E, Ghaffarifar F, Sharifi Z, Dalimi A, Jorjani O. The role of IL-12 in protective immunity against Leishmania: a comprehensive review. Iran J Parasitol. 2023; 18 (2): 189-203.
13. Michel MY, Fathy FM, Hegazy EH, Hussein ED, Eissa MM, Said DE. The adjuvant effects of IL-12 and BCG on autoclaved Leishmania major vaccine in experimental cutaneous leishmaniasis. J Egypt Soc Parasitol. 2006; 36 (1): 159-76.
14. Jorjani O, Ghaffarifar F, Sharifi Z, Dalimi A, Ziaei-Hezarjaribi H, Talebi B. LACK gene's immune response induced by cocktail DNA vaccine with IL-12 gene against cutaneous leishmaniasis in BALB/c mice. Avicenna J Med Biotechnol. 2018; 10 (3): 134-40.
15. Wojno EDT, Hunter CA, Stumhofer JS. The immunobiology of the interleukin-12 family: room for discovery. Immunity. 2019; 50 (4): 851-70. [DOI:10.1016/j.immuni.2019.03.011] [PMID] [PMCID]
16. Zhang H, Wang Y, Wang QT, Sun SN, Li SY, Shang H, et al. Enhanced human T lymphocyte antigen priming by cytokine-matured dendritic cells overexpressing Bcl-2 and IL-12. Front Cell Dev Biol. 2020; 8: 205. [DOI:10.3389/fcell.2020.00205] [PMID] [PMCID]
17. Donyavi T, Bandehpour M, Kazemi B. Preparation of transgenic Iranian lizard Leishmania‌ coding hIL-12. Iran J Microbiol. 2017; 9 (5): 305-11.
18. Kazemi B, Tahvidar-Bideroni GH, Hashemi-Feshareki SR, Javadian E. Isolation a lizard leishmania promastigote from its natural host in Iran. J Biol Sci. 2004; 4 (5): 620-3. [DOI:10.3923/jbs.2004.620.623]
19. Preparation of Leishmania antigen [Internet]. Bio-protocol; 2011 [cited 2025 Apr 29]. Available from: https://bio-protocol.org/exchange/minidetail?id=21879196&type=30
20. He F. Bradford protein assay. Bio Protocol [Internet]. 2011; 1 (6): e45. Available from: https://bio-protocol.org/pdf/bio-protocol45.pdf [DOI:10.21769/BioProtoc.45]
21. National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press; 2011.
22. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AST, et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun. 2004; 72 (10): 5654-61. [DOI:10.1128/IAI.72.10.5654-5661.2004] [PMID] [PMCID]
23. Mayrink W, dos Santos GC, de Toledo VDPCP, Guimarães TMPD, Machado-Coelho GLL, Genaro O, et al. Vaccination of C57BL/10 mice against cutaneous leishmaniasis using killed promastigotes of different strains and species of Leishmania. Rev Soc Bras Med Trop. 2002; 35 (2): 125-32. [DOI:10.1590/S0037-86822002000200001] [PMID]
24. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010; 1 (2): 87-93. [DOI:10.4103/0976-500X.72350] [PMID] [PMCID]
25. Martínez ST, Manuel AM. Experimental protocol: isolation of PBMCs by Ficoll-Paque density gradient centrifugation [Internet]. Madrid: CIBERONC; 2015 [cited 2025 Apr 29]. Available from: https://inmuno-oncologia.ciberonc.es/media/xyfhpmdq/experimental-protocol_ficoll-paque-density-gradient-centrifugation.pdf
26. Coquery CM, Loo W, Buszko M, Lannigan J, Erickson LD. Optimized protocol for the isolation of spleen-resident murine neutrophils. Cytometry A. 2012; 81 (9): 806-14. [DOI:10.1002/cyto.a.22096] [PMID] [PMCID]
27. Meng F, Lowell CA. Lipopolysaccharide (LPS)-induced macrophage activation and signal transduction in the absence of Src-family kinases Hck, Fgr, and Lyn. J Exp Med. 1997; 185 (9): 1661-70. [DOI:10.1084/jem.185.9.1661] [PMID] [PMCID]
28. Nicolas L, Prina E, Lang T, Milon G. Real-time PCR for detection and quantitation of Leishmania in mouse tissues. J Clin Microbiol. 2002; 40 (5): 1666-9. [DOI:10.1128/JCM.40.5.1666-1669.2002] [PMID] [PMCID]
29. Nicolas L, Sidjanski S, Colle JH, Milon G. Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice. Infect Immun. 2000; 68 (12): 6561-6. [DOI:10.1128/IAI.68.12.6561-6566.2000] [PMID] [PMCID]
30. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol. 1983; 166 (4): 557-80. [DOI:10.1016/S0022-2836(83)80284-8] [PMID]
31. Omni Calculator. DNA copy number calculator [Internet]. 2024 [cited 2025 Apr 29]. Available from: https://www.omnicalculator.com/biology/dna-copy-number#formula-for-the-dnarna-copy-number
32. Molekula. Diluting concentrated stocks: C1V1 = C2V2 and serial dilutions [Internet]. 2026 [cited 2025 Apr 29]. Available from: https://molekula.com/articles/diluting-concentrated-stocks-c1v1-c2v2-and-serial-dilutions
33. Gorak PM, Engwerda CR, Kaye PM. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur J Immunol. 1998; 28 (2): 687-95. https://doi.org/10.1002/(SICI)1521-4141(199802)28:02<687::AID-IMMU687>3.0.CO;2-N [DOI:10.1002/(SICI)1521-4141(199802)28:023.0.CO;2-N]
34. Hamza T, Barnett JB, Li B. Interleukin 12: a key immunoregulatory cytokine in infection applications. Int J Mol Sci. 2010; 11 (3): 789-806. [DOI:10.3390/ijms11030789] [PMID] [PMCID]
35. Ness S, Lin S, Gordon JR. Regulatory dendritic cells, T cell tolerance, and dendritic cell therapy for immunologic disease. Front Immunol. 2021; 12: 633436. [DOI:10.3389/fimmu.2021.633436] [PMID] [PMCID]
36. Gannavaram S, Bhattacharya P, Dey R, Joshi AB, Akopyants NS, Beverley SM, et al. Centrin gene deletion in Leishmania reveals IL-12-dependent protective immunity. Front Immunol. 2021; 12: 745678.
37. Himmelrich H, Parra-Lopez C, Tacchini-Cottier F, Louis JA, Launois P. The IL-4 rapidly produced in BALB/c mice after infection with Leishmania major down-regulates IL-12 receptor β2-chain expression on CD4+ T cells resulting in a state of unresponsiveness to IL-12. J Immunol. 1998; 161 (11): 6156-63. [DOI:10.4049/jimmunol.161.11.6156] [PMID]
38. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3 (2): 133-46. [DOI:10.1038/nri1001] [PMID] [PMCID]
39. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis: evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989; 169 (1): 59-72. [DOI:10.1084/jem.169.1.59] [PMID] [PMCID]
40. Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012; 3: 144. [DOI:10.3389/fimmu.2012.00144] [PMID] [PMCID]
41. Goto Y, Mizobuchi H. Pathological roles of macrophages in Leishmania infections. Parasitol Int. 2023; 94: 102738. [DOI:10.1016/j.parint.2023.102738] [PMID]
42. Olías-Molero AI, Moreno I, Corral MJ, Jiménez-Antón MD, Day MJ, Domínguez M, et al. Infection of dogs by Leishmania infantum elicits a general response of IgG subclasses. Sci Rep. 2020; 10 (1): 18826. [DOI:10.1038/s41598-020-75569-6] [PMID] [PMCID]
43. Panaro MA, Brandonisio O, de Caprariis D, Cavallo P, Cianciulli A, Mitolo V, et al. Canine leishmaniasis in Southern Italy: a role for nitric oxide released from activated macrophages in asymptomatic infection? Parasit Vectors. 2008; 1 (1): 10. [DOI:10.1186/1756-3305-1-10] [PMID] [PMCID]
44. Banerjee A, Bhattacharya P, Joshi AB, Ismail N, Dey R, Nakhasi HL. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol. 2016; 309: 37-41. [DOI:10.1016/j.cellimm.2016.07.004] [PMID]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.